

INTERNATIONAL STANDARD

ISO 15798

Second edition
2010-02-01

Ophthalmic implants — Ophthalmic viscosurgical devices

Implants ophtalmiques — Dispositifs ophtalmiques viscoélastiques



Reference number
ISO 15798:2010(E)

© ISO 2010

PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.



COPYRIGHT PROTECTED DOCUMENT

© ISO 2010

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword	iv
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 Intended performance	4
5 Design attributes	4
5.1 General	4
5.2 Characterization of the components	4
5.3 Characterization of the finished product	4
6 Design evaluation	6
6.1 General	6
6.2 Evaluation of biological safety	7
6.3 Clinical evaluation	8
7 Sterilization	10
8 Product stability	10
9 Integrity and performance of the delivery system	10
10 Packaging	10
10.1 Protection from damage during storage and transport	10
10.2 Maintenance of sterility in transit	10
11 Information to be supplied by the manufacturer	11
Annex A (normative) Intraocular implantation test	12
Annex B (informative) Patient numbers for clinical investigation of intra-ocular pressure	15
Bibliography	16

Copyright International Organization for Standardization

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 15798 was prepared by Technical Committee ISO/TC 172, *Optics and photonics*, Subcommittee SC 7, *Ophthalmic optics and instruments*.

This second edition cancels and replaces the first edition (ISO 15798:2001) which has been technically revised. It also includes the Technical Corrigendum ISO 15798:2001/Cor 1:2003.

Ophthalmic implants — Ophthalmic viscosurgical devices

1 Scope

This International Standard is applicable to ophthalmic viscosurgical devices (OVDs), a class of non-active surgical implants with viscous and/or viscoelastic properties, intended for use during surgery in the anterior segment of the human eye. OVDs are designed to create and maintain space, to protect intra-ocular tissues and to manipulate tissues during surgery.

This International Standard specifies requirements with regard to safety for the intended performance, design attributes, preclinical and clinical evaluation, sterilization, product packaging, product labelling and information supplied by the manufacturer of these devices.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 10993-6, *Biological evaluation of medical devices — Part 6: Tests for local effects after implantation*

ISO 10993-9, *Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products*

ISO 10993-16, *Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables*

ISO 11135-1, *Sterilization of health care products — Ethylene oxide — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11137-1, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11137-2, *Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose*

ISO 11137-3, *Sterilization of health care products — Radiation — Part 3: Guidance on dosimetric aspects*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 13408-1, *Aseptic processing of health care products — Part 1: General requirements*

ISO 14155-1, *Clinical investigation of medical devices for human subjects — Part 1: General requirements*

ISO 14155-2, *Clinical investigation of medical devices for human subjects — Part 2: Clinical investigation plans*

ISO 14630, *Non-active surgical implants — General requirements*

ISO 14971, *Medical devices — Application of risk management to medical devices*

ISO 15223-1, *Medical devices — Symbols to be used with medical device labels, labelling and information to be supplied — Part 1: General requirements*

ISO 15223-2, *Medical devices — Symbols to be used with medical device labels, labelling and information to be supplied — Part 2: Symbol development, selection and validation*

ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 22442-1, *Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management*

ISO 22442-2, *Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling*

ISO 22442-3, *Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents*

EN 980, *Symbols for use in the labelling of medical devices*

EN 1041, *Information supplied by the manufacturer of medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

absolute complex viscosity

$$|\eta^*| = [(\eta')^2 + (\eta'')^2]^{0,5}$$

absolute value of complex viscosity (3.2)

NOTE Absolute complex viscosity is expressed in pascal seconds (Pa·s).

3.2

complex viscosity

$$\eta^* = \eta' - i \cdot \eta''$$

viscosity consisting of a viscous η' and an elastic η'' component where i is an imaginary number defined by $i = (-1)^{0,5}$

3.3

delivery system

sealed container in which the product is supplied and any additional components provided to introduce the product into the eye

3.4

elasticity

tendency of a body to return to its original shape after having been deformed

NOTE Elasticity is quantitatively defined as stress (the force generated within the body) divided by strain (the change in dimensions of the body).

3.5**lost to follow-up subject**

subject for which the final post-operative case report form is overdue and who cannot be contacted despite extensive written and telephone follow-ups to determine the final clinical outcome

NOTE This category does not include subjects who have died.

3.6**ophthalmic viscosurgical device****OVD**

generic term that includes a variety of materials with viscous and/or viscoelastic properties, which are designed to create and maintain space, to protect intra-ocular tissues and to manipulate tissues during surgery in the anterior segment of the human eye

3.7**primary container**

vial or syringe that contains the OVD

NOTE This container forms part of the delivery system.

3.8**rheologically active component**

compound or mixture of compounds in the finished OVD giving the product viscous and/or viscoelastic properties

3.9**shear viscosity**

tendency of a fluid to resist flow when subjected to stress

NOTE 1 Quantitatively, shear viscosity is the quotient of shear stress divided by shear rate in steady shear flow.

NOTE 2 Shear viscosity is expressed in pascal seconds (Pa·s), traditionally in millipascal seconds (mPa·s).

NOTE 3 Shear rate is the velocity gradient in a flowing fluid, expressed in s^{-1} (per second).

NOTE 4 The shear viscosity divided by the solution density gives the *kinematic viscosity*, which is a measure of the viscosity of a fluid influenced by inertia (e.g. gravity).

3.10**sterile barrier**

sealed packaging, containing the product and delivery system, which maintains sterility during transport and storage

3.11**storage container**

that part of the packaging intended to protect the device during transport and storage, containing the sterile barrier

3.12**viscoelasticity**

characteristics of a fluid having both viscous and elastic properties

NOTE The viscous modulus, G'' , is frequently called the loss modulus and the elastic modulus, G' , is frequently called the storage modulus, both moduli are expressed in Pascal (Pa). The moduli can be combined to show the elasticity of the OVD (see 5.3.5).

3.13**zero shear viscosity**

plateau viscosity at vanishing shear rate in a log-log plot of viscosity versus shear rate

NOTE Zero shear viscosity is expressed in pascal seconds (Pa·s), traditionally in millipascal seconds (mPa·s), or as a logarithm of the zero shear viscosity.

4 Intended performance

The general requirements for the intended performance of non-active surgical implants outlined in ISO 14630 shall apply. In addition, the manufacturer shall describe and document the functional characteristics of the OVD in terms of its

- a) chemical composition;
- b) rheological properties;
- c) performance in protecting the corneal endothelium.

5 Design attributes

5.1 General

The general requirements for non-active surgical implants outlined in ISO 14630 shall apply.

NOTE Tests described herein are intended to apply when qualifying materials but not necessarily apply as a routine quality assurance/control programme.

The purity of water used shall be water for injection.

A risk assessment shall be performed in accordance with ISO 14971.

5.2 Characterization of the components

The manufacturer shall provide a description of each rheologically active component, quantitatively and qualitatively, in the product.

The raw materials used in the manufacture of the product shall be listed qualitatively, along with their quality specifications. These shall comply with recognized compendial standards wherever possible.

If the rheologically active component is derived from animal sources, the requirements of ISO 22442-1, ISO 22442-2, and ISO 22442-3 shall apply.

If the rheologically active component is a high-molecular mass synthetic polymer, the repeating subunits that comprise it shall be chemically identified and the linkages between them described. Any cross linking shall also be described.

5.3 Characterization of the finished product

5.3.1 General

All testing requirements described in 5.3.2 to 5.3.12 shall be performed with the finished, sterilized product. The rheological and optical properties of OVDs are physical characteristics that determine their performance in ophthalmic surgery. It is therefore imperative that the physical properties of OVDs identified below are fully and accurately described. The rheological properties shall be measured under the conditions expected and relevant at the time of use, and be reported.

5.3.2 Absolute complex viscosity

The logarithm of the absolute complex viscosity versus the logarithm of the oscillation frequency shall be graphed to simultaneously demonstrate the resistance to flow and deformation of the OVD formulation. At very low frequencies the absolute complex viscosity approaches the zero shear viscosity.

NOTE Complex viscosity should, if possible, be determined at frequencies between (10^{-3} to 10^3) Hz (s^{-1}). For products of very high viscosity ($>2 \times 10^3$ Pa·s), frequencies below 0,01 Hz will be required to show the zero shear viscosity.

5.3.3 Chemical and biological contaminants

All chemical or biological contaminants shall be identified and their potential ocular hazard shall be determined by risk analysis. For raw materials of biological origin, these contaminants can include proteins, nucleic acids or other biological materials. Contaminants derived from the source materials or from the manufacturing process, e.g. cross linking agents and antioxidants, shall be identified whenever possible, and their concentrations in the finished product shall be reported.

Contaminants shall be determined using standard analytical methods, when available, and all methods shall be described. Limits for identified contaminants shall be set and included. Testing for the biological effects of these contaminants during evaluation of biological safety is required, if the risk analysis deems it necessary.

NOTE Droplets of silicone lubricant, derived from the syringe, are frequent contaminants, often misinterpreted as air bubbles or particulates. Contamination of the product from this source should be considered in the risk assessment.

5.3.4 Concentration

The concentration of each rheologically active component material shall be reported as weight of material per unit volume of solution. Since the testing methodology may affect the actual concentration reported, the standard physical or chemical techniques utilized shall be described.

5.3.5 Elasticity

The elasticity of the OVD shall be demonstrated at the same frequencies used to determine the complex viscosity. It shall be demonstrated up to at least 100 Hz. Measurements shall be made at $25\text{ °C} \pm 2\text{ °C}$. The test equipment and other conditions of measurement shall be documented. Both the log viscous, G'' , and log elastic, G' , moduli shall be plotted against the log frequency. Data can also be presented as a plot of percent elasticity against log frequency, for example as $100 \times [G'/(G'+G'')]$ versus log frequency.

5.3.6 Molecular mass distribution

If the rheologically active component of the OVD is a polymer, the mass average relative molecular mass shall be reported.

It is recognized that many OVDs contain high molecular mass polymers that are polydisperse and that the molecular mass distribution may be complex. In these circumstances the manufacturer shall conduct and report such additional tests as are necessary to provide an adequate description of the molecular mass distribution of the components. Standard methods shall be used wherever possible.

5.3.7 Osmolality

The manufacturer shall determine and document the osmolality range of the OVD. Osmolality of the finished product shall not be less than 200 mOsm/kg or greater than 400 mOsm/kg. Osmolality shall be determined using either a vapour pressure or a cryoscopic osmometer under standard conditions.

5.3.8 Particulates

A risk assessment shall evaluate the potential for contamination by, or formation of, particulates in the product during manufacture, the conditions expected during transport and storage and during use of the product. In particular the potential for aggregation, polymerization and adhesion of particles to ocular tissues shall be taken into account.

NOTE OVDs containing synthetic polymers are likely to be at significantly higher risk of formation of microgels, which are difficult to identify and quantify.

The manufacturer shall identify the potential hazards associated with each type of particle identified by the risk assessment.

The manufacturer shall characterize the types, range of sizes and levels of particulates present using a validated method.

A limit for the overall number of particles (e.g., $\geq 10 \mu\text{m}$ and $\geq 25 \mu\text{m}$) present, and a limit for each type of particle identified by the risk analysis as a potential ocular hazard at the levels allowed by the overall particle specification, shall be set and an adequate justification for the limits shall be documented.

5.3.9 pH

The pH of the finished product shall be measured with a calibrated pH meter at $25^\circ\text{C} \pm 2^\circ\text{C}$. The pH of the product shall be between 6,8 and 7,6.

NOTE The pH meter should be fitted with an electrode suitable for high viscosity solutions. The pH of the product should be close to that of the aqueous humour (pH 7,38) in order to prevent damage to the corneal endothelial cells. *In vitro* studies have shown that the pH range tolerated by the endothelium narrows as exposure time increases.

5.3.10 Refractive index

The refractive index between air and the OVD shall be measured with a refractometer at $25^\circ\text{C} \pm 2^\circ\text{C}$ stating at which wavelength it was determined.

5.3.11 Shear viscosity

The shear viscosity of the product as provided to the end-user shall be measured over the range of shear rates that are likely to be encountered during routine use of the device. Measurements shall be made at $25^\circ\text{C} \pm 2^\circ\text{C}$. The test results, equipment and conditions of measurement shall be documented.

NOTE The suggested shear rate range is from $0,001 \text{ s}^{-1}$ at one extreme, approximate to zero shear, when the viscoelastic fluid is stationary, for example within the anterior chamber, to a shear rate of approximately $1\,000 \text{ s}^{-1}$ at the other extreme, approximate to the conditions when the viscoelastic fluid is being injected into the eye through a cannula. It is recognised that, for products of low viscosity, it is problematic to measure the shear viscosity at very low shear rates. In such circumstances the viscosity can be measured at shear rates from $1\,000 \text{ s}^{-1}$ to the lowest shear rate at which the viscosity can be practically determined. For products of very high viscosity ($>2 \times 10^3 \text{ Pa}\cdot\text{s}$), shear rates below $0,001 \text{ s}^{-1}$ might be required to determine the zero shear viscosity.

The viscosity-shear rate relationship shall be graphically presented on a standard plot of log viscosity versus log shear rate. The zero shear viscosity is determined as the steady shear plateau viscosity at vanishing shear rate. For highly viscous formulations, measurement with a controlled stress rheometer is preferred.

5.3.12 Spectral transmittance

The spectral transmittance shall be recorded over the range 300 nm to 1 100 nm. Results shall be presented graphically, plotting percent transmission against wavelength.

6 Design evaluation

6.1 General

The requirements for evaluation of non-active implants outlined in ISO 14630 shall apply.

6.2 Evaluation of biological safety

6.2.1 General

The procedure for evaluation of biological safety of an OVD shall commence with an assessment of risk, carried out and documented in accordance with ISO 14971. The results of the risk analysis shall determine the tests required to evaluate the biological safety of the OVD.

For OVDs containing material of animal origin, the risk analysis and management requirements outlined in ISO 22442-1, ISO 22442-2, and ISO 22442-3 shall apply.

For all OVDs the requirements for evaluation of biological safety specified in ISO 10993-1 shall apply, together with the following particular requirements.

In addition to the biocompatibility tests identified in ISO 10993-1 and by the risk analysis, all of the following tests shall be considered in the selection of tests to evaluate the biological safety of an OVD.

NOTE 1 Based upon the typical clinical applications in the anterior segment of the eye, OVDs are categorized as "Implant devices, tissue/bone". The tests for this and other categories of device identified in Table 1 of ISO 10993-1 are for guidance only; they do not represent maximum or minimum test requirements.

NOTE 2 It may be possible to combine biocompatibility tests, thereby reducing the number of animals required for testing. Two tests can be conducted simultaneously in a single animal provided that the test animal is not subjected to undue pain or distress.

6.2.2 Bacterial endotoxins test

The OVD shall be evaluated for the presence of bacterial endotoxins using the limulus amoebocyte lysate (LAL) test, in accordance with applicable Pharmacopoeia (see Bibliography). Any product that exceeds a bacterial endotoxin limit of 0,5 endotoxin units (EU) per millilitre fails the test.

6.2.3 Clearance of residual OVD from the anterior chamber

Where no adequate literature exists, the rate at which residual product is cleared from the anterior chamber through the trabecular meshwork shall be determined using an appropriate test method, such as fluorescence or radioisotope labelling, and then reported.

6.2.4 Degradation and toxicokinetics

Where no adequate literature exists concerning the fate of the OVD, the manufacturer shall provide evidence of the route of elimination, biotransformation and catabolic products of the components. With regard to degradation and toxicokinetics, the requirements of ISO 10993-9 and ISO 10993-16 shall apply.

6.2.5 Evaluation of inflammation and intraocular pressure

A test for inflammatory and intraocular pressure responses shall be performed to compare the test OVD with a control OVD in accordance with the procedure outlined in Annex A. The control OVD shall have been widely used for at least five years and not have been associated with significant material-related adverse events. A rationale for the choice of the control OVD shall be given.

The general requirements for implantation tests outlined in ISO 10993-6 shall apply. The particular requirements for the intraocular implantation test are outlined in Annex A.

If the test OVD causes a significantly higher or more prolonged inflammation or IOP increase than the OVD used as control, a risk/benefit evaluation shall be performed.

The results of the test shall be used to determine the likely magnitude and duration of the post-surgical inflammatory reaction and pressure rise. This will influence the design of the clinical investigation and may necessitate additional post-surgical time points for the measurement of IOP in addition to those listed in 6.3.5.

In accordance with ISO 10993-2, animal testing should be reduced to the justifiable minimum.

6.3 Clinical evaluation

6.3.1 General

If the risk assessment indicates a need for, or if regional or national regulations require, a clinical evaluation, the following applies.

The general requirements concerning clinical investigations of medical devices for human subjects specified in ISO 14155-1 and ISO 14155-2 shall apply, together with the following particular requirements.

6.3.2 Clinical investigation design

A randomized controlled clinical investigation shall be performed. The objective of the study shall be to document the safety and performance of the new OVD when compared to a well documented control OVD. The surgical procedure shall be described in detail in the clinical investigation plan (CIP) including the type of any implant used.

The control shall be an OVD with physical properties relevant for the surgical procedure to be applied. The product shall have been widely used for at least five years and be approved for the same indication as the study OVD. A rationale for the choice of control shall be given in the CIP.

If a true masked study comparing the new OVD and the control cannot be achieved, an independent observer, who is unaware of which device has been used in each case, shall perform the postoperative measurements.

A risk analysis shall determine the primary hypothesis, and standard biostatistical formulæ shall be used to calculate the required number of subjects per treatment group. A method to determine the number of subjects is provided in Annex B. If the manufacturer wishes to make claims, e.g. regarding the intra operative performance of the device, specific endpoints to support those claims shall be included in the CIP together with the appropriate power calculation.

A subject may only submit one eye in the investigation.

No investigator shall contribute less than 20 subjects or more than 25 % of the total number of subjects in the investigation.

NOTE Investigations conducted at a single site may result in additional regulations in some countries.

Efforts shall be made to keep the number of patients lost to follow up below 10 % of the number enrolled.

The following variables shall be evaluated during the clinical investigation.

- a) Intraocular pressure
- b) Corneal endothelial cell density
- c) Intraocular inflammation

The CIP shall include a description of the analyses to be performed. Some suggested analyses comparing the two OVDs are

- 1) endothelial cell density changes;
- 2) mean IOP at each follow-up;

- 3) IOP \geq 30 mmHg at any follow-up;
- 4) grade of inflammation at each follow-up.

6.3.3 Corneal endothelial cell density

The condition of the corneal endothelium shall be assessed by measuring central corneal endothelial cell density pre-operatively and 3 months \pm 2 weeks postoperatively on all subjects in the investigation.

6.3.4 Postoperative inflammation

Postoperative inflammation shall be evaluated by slit-lamp biomicroscopy and graded clinically at each visit.

6.3.5 Post-operative intra-ocular pressure change

The intra-ocular pressure shall be measured using a Goldmann type applanation tonometer pre-operatively and at least at the following times postoperatively:

- a) 6 h \pm 2 h
- b) 24 h \pm 4 h
- c) 7 d \pm 2 d
- d) 30 d \pm 7 d
- e) 90 d \pm 14 d

If a literature review, animal testing, or clinical experience indicates that the peak IOP occurs at a time outside the 4 h to 8 h postoperative range, the manufacturer shall modify the clinical investigational design to measure the IOP at times closer to the predicted appearance of the peak, for both the test and the control group.

When IOP in an individual subject is elevated at 24 h after surgery, additional IOP measurements shall be performed until the IOP normalizes. The magnitude of the IOP elevation and the frequency of the additional IOP measurements shall be described in the CIP.

The criteria and protocol for use of IOP lowering drugs or interventions shall be specified in the CIP. The administration, at any time, of IOP-reducing drugs, or other interventions, shall be documented and the data from those subjects shall be presented separately.

If any subject in the investigation has an IOP \geq 30 mmHg at one week or later, early termination of the investigation shall be considered. This analysis shall be performed during the study for all subjects and at the end of the study for each treatment group. At the completion of the study, analysis of the IOP measurements at the required time points shall include calculations of the means as well as the frequencies of IOP values \geq 30 mmHg.

6.3.6 Adverse events

Clinical investigators shall file reports of serious intra-operative and post-operative adverse events with the sponsor immediately after learning of their occurrence. These and all other adverse events shall be documented in the case reports. Manufacturers shall take into account adverse events reports when reviewing their risk analysis.

7 Sterilization

Wherever possible, the product shall be terminally sterilized. The requirements for sterilization of non-active surgical implants outlined in ISO 14630 shall apply.

For an OVD, or components thereof, sterilized using moist heat, the requirements of ISO 17665-1 shall apply.

For an OVD, or components thereof, sterilized by radiation, the requirements of ISO 11137-1, ISO 11137-2 and ISO 11137-3 shall apply.

NOTE 1 It is recognised that many OVDs contain high molecular mass polymers that are labile and that the rheological properties of the product can be adversely influenced by sterilization with moist heat or radiation. When a product cannot be terminally sterilized by moist heat or radiation, aseptic processing is an accepted alternative.

For OVDs that are aseptically processed, the requirements specified in ISO 13408-1 shall apply.

For components of an OVD sterilized using ethylene oxide, the requirements of ISO 11135-1 shall apply. The potential for EO derived reaction products in the OVD shall be taken into account in the risk analysis.

NOTE 2 The OVD itself, being an aqueous solution, cannot be sterilized by EO, but EO can diffuse into the OVD if the packaging containing it is sterilized with EO. If so EO will immediately react with water to form derivatives (e.g. ethylene glycol, ethylene chlorohydrin).

8 Product stability

The manufacturer shall define and state the shelf life of the OVD and its delivery system. Real time or validated accelerated (at temperatures not to exceed 45 °C) shelf-life testing shall be performed to demonstrate that the essential characteristics for safe and effective performance of the finished product and delivery system remain within product specifications over the labelled shelf life under expected conditions of transport and storage. The parameters that shall be followed during shelf-life studies are the rheological profile, pH and sterility, plus any other factors identified by risk analysis as crucial for the use of the product.

Changes in the composition of the product, source materials, material suppliers, manufacturing conditions, including the sterilization process, package design or package materials may affect the shelf life of the product. The established shelf life of the OVD shall be revalidated if a risk assessment identifies any change in manufacture that may affect the stability of the product.

9 Integrity and performance of the delivery system

An OVD is typically supplied in a sealed container, and is often accompanied by a cannula for injection of the product into the eye. These two components comprise the delivery system. Appropriate testing shall demonstrate that mechanical failure of the delivery system will not result from intended use.

Chemical and physical compatibility of the OVD and the delivery system and biocompatibility of the components of the delivery system shall be evaluated.

10 Packaging

10.1 Protection from damage during storage and transport

The packaging requirements for medical devices outlined in ISO 11607-1 and ISO 14630 shall apply.

10.2 Maintenance of sterility in transit

OVDs shall be packaged in such a way that they remain sterile within the limits specified for conditions of transport, storage and handling. The sterile packaging requirements outlined in ISO 11607-1 shall apply.

11 Information to be supplied by the manufacturer

The general requirements for information provided by the manufacturer of medical devices specified in EN 1041 shall apply, together with the following particular requirements for viscosurgical devices. Symbols may be used instead of text, where appropriate. When symbols are used, ISO 15223-1, ISO 15223-2 or EN 980, depending on region, apply.

If the product is vulnerable to damage by exposure to environmental elements, there shall be clear warning signs on the shipping container.

The batch number and expiration date may also be provided on a self-adhesive label for use in records.

Instructions for use shall be included within the storage container, provided in such a way that it can be read without damaging the sterile barrier.

The minimum information required on the storage container, instructions for use, sterile barrier and primary container is listed in Table 1.

Table 1 — Information to be supplied by the manufacturer

Point of information	Storage container	Instructions for use	Sterile barrier	Primary container
Name or trade name and address of the manufacturer, and name and address of the authorized representative, if applicable	X	X		
Name or trade name of the manufacturer			X	
Trade name of product	X	X	X	
Description of the delivery system and instructions for its proper use		X		
Brief description of the chemical composition of the product and the volume supplied	X	X		
Description of the relevant design attributes that may affect the safety and performance of the product, including, but not limited to, all of the following: concentration; molecular mass distribution; pH; osmolality		X		
Graphical presentation of the rheological profile, plotting the log viscosity (Pa·s) vs log shear rate (s^{-1}) over the range defined in 5.3.11		X		
Conditions for storage	X	X		
Indications for use		X		
Contra-indications for use		X		
Instructions for use, including recommendations for removal of the product if necessary		X		
Warnings and precautions		X		
Statement "For single use"	X	X	X ^a	
Statement "Sterile" and the method(s) of sterilization of the product and primary container	X	X	X ^a	
Statement "Do not use if sterile barrier is breached"			X ^a	
Expiration date	X		X ^a	X
Batch number preceded by the word "LOT"	X		X ^a	X
Date of issue or the latest revision of the instructions for use		X		

^a This, or part of this, information can be alternatively given on the primary container and need not be provided on the sterile barrier if that is transparent and the required information is given on and can be read directly from the primary container without breaking the seal. Irrespective of choice, expiration data and batch number shall in all cases be given on the primary container.

Annex A (normative)

Intraocular implantation test

A.1 General

A transient increase in intra-ocular pressure (IOP) and an inflammatory reaction can follow anterior segment surgery in which OVDs are utilized. It is an accepted consequence of their use, and should not significantly impair ocular function or the repair of ocular tissues. A significant or prolonged increase in the IOP can cause pain or discomfort and result in permanent damage to the eye. This test monitors the rise in the intraocular pressure and any inflammatory reaction, following replacement of aqueous humour by an equal volume of OVD in the anterior chamber of a suitable test animal. The OVD remains in the eye; thus the test does not mimic clinical use, where the surgeon removes as much of the OVD as possible prior to closure of the incision. Thus the duration and magnitude of the change in IOP during preclinical testing can be greater than that encountered during clinical use. This test is only for comparison of the OVD with a control material approved for the same use.

A.2 Test material

The sterile finished OVD under investigation is used as test material.

A.3 Control material

Choose a control OVD that has been widely used for at least five years and has not been associated with significant material related adverse events. Give a rationale for the choice of the control OVD. Use It in the same form as supplied to the market.

A.4 Test procedure

Use a minimum of six animals for the test. If rabbits are used, they should preferably be of the New Zealand white strain and weigh approximately 2,5 kg.

First evaluate the eyes pre-operatively using applanation tonometry, slit-lamp biomicroscopy and pachymetry then record the results. Reject animals with abnormalities in any eye.

Appoint a person with experience in surgery on the ocular anterior segment to perform the implantations.

Exchange approximately 25 % of the liquid volume in the anterior chamber with the test OVD, in one eye of the test animal. The contra lateral eye is treated in the same way with the control OVD. The eyes of each animal are treated one after the other, preferably in a randomized order, before continuing with the next animal. Record intra-operative complications, if any.

NOTE 1 A bilateral implantation is preferred, but unilateral implantation is permitted, if local regulations so require. In this case a minimum of twelve animals should be used.

NOTE 2 Implantation should be achieved with the minimum possible trauma to the eye to avoid physical damage to ocular tissue, which can mask the intraocular changes resulting from exposure to the test or control material.

A.5 Test evaluation

A.5.1 Intraocular pressure evaluation

Measure the intraocular pressure by applanation tonometry at the following times, post-operatively:

- a) 2 h \pm 0,5 h
- b) 4 h \pm 1 h
- c) 6 h \pm 1 h
- d) 8 h \pm 1 h
- e) 12 h \pm 1 h
- f) 24 h \pm 2 h
- g) 7 d \pm 1 d

The rate of change of the intraocular pressure and duration can vary considerably with the nature of the OVD and in particular its viscosity. Once a pattern has been established, the times at which the intraocular pressure is measured can be altered to more accurately follow its change. Additional evaluation times may be necessary if the IOP remains elevated for more than 24 h post-injection. Document all test results.

A.5.2 Inflammatory response evaluation

The inflammatory response is monitored and graded according to a standardized ocular scoring system for slit-lamp biomicroscopic examination and pachymetry at the following times post-operatively:

- a) 6 h \pm 1 h
- b) 24 h \pm 2 h
- c) 48 h \pm 2 h
- d) 72 h \pm 2 h
- e) 7 d \pm 1 d

Additional evaluation times may be necessary if an inflammatory response is noted.

The slit-lamp observations should include at least the following:

- a) corneal clarity;
- b) cells;
- c) fibrin;
- d) flare;
- e) iritis;
- f) lens clarity.

Document all test results.

A.6 Test report

Report, as a minimum, the following:

- a) all information necessary for identification of the samples tested;
- b) the results of the test, including the results of the individual determinations and their means, where applicable;
- c) any deviations from the procedure specified;
- d) any unusual features (anomalies) observed during the test;
- e) dates for all surgery, tests and subsequent analyses.

11

Annex B (informative)

Patient numbers for clinical investigation of intra-ocular pressure

The sample size calculation for the study is based on an increase in intra-ocular pressure (IOP) as the primary endpoint. A transient increase in the IOP is the main safety concern with currently used OVDs. The clinical investigation is designed to compare the test product with the control in terms of the incidence of IOP observations above 30 mmHg.

The null hypothesis, H_0 , is that the test incidence, Π_t , of IOP observations above 30 mmHg minus the control incidence, Π_c , of IOP observations above 30 mmHg is greater than or equal to the minimally detectable difference, δ , between the two incidences.

The alternative hypothesis, H_1 , is that the test incidence, Π_t , of IOP observations above 30 mmHg minus the control incidence, Π_c , of IOP observations above 30 mmHg is less than the minimally detectable difference, δ , between the two incidences.

Thus:

$$H_0: \Pi_t - \Pi_c \geq \delta$$

$$H_1: \Pi_t - \Pi_c < \delta$$

The minimum number, N , of evaluable patients necessary for each treatment group is determined by the equation below:

$$N = \frac{(z_{1-\beta} + z_{1-\alpha})^2 \times [\Pi_t \times (1 - \Pi_t) + \Pi_c \times (1 - \Pi_c)]}{\delta^2}$$

Assuming a control incidence, Π_c , and a test incidence, Π_t , of 0,10, a minimally detectable difference, δ , of 0,10, a power $(1-\beta)$ of 0,80, and an α of 0,05, the minimum number of evaluable patients per treatment group is given by:

$$N = \frac{(0,842 + 1,282)^2 \times [0,1 \times (0,9) + 0,1 \times (0,9)]}{0,10^2} \approx 112$$

It should be noted that the control incidence can vary substantially from the incidence of 0,10 used in this example. In cases where the incidence, Π_c , of IOL observations greater than 30 mmHg for the control OVD chosen is believed to be substantially different from 0,10, it will be necessary to recalculate the sample size for the investigation.

Bibliography

- [1] European Pharmacopoeia, Appendix XIV C. Test for Bacterial Endotoxins
- [2] Japanese Pharmacopoeia, XIV 6. Bacterial Endotoxins Test
- [3] United States Pharmacopoeia, <85> Bacterial Endotoxins Test

